Holen Sie sich die Stockscreener-App
0.617
2.83%
0.017
Schlusskurs vom Vortag:
$0.60
Offen:
$0.63
24-Stunden-Volumen:
256.77K
Relative Volume:
0.36
Marktkapitalisierung:
$38.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-68.80M
KGV:
-0.5274
EPS:
-1.17
Netto-Cashflow:
$-59.06M
1W Leistung:
+3.35%
1M Leistung:
-6.52%
6M Leistung:
-31.44%
1J Leistung:
-31.36%
1-Tages-Spanne:
$0.5976
$0.63
1-Wochen-Bereich:
$0.5606
$0.642
52-Wochen-Spanne:
$0.451
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Vergleichen Sie PASG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.617 | 38.11M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics - MSN
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Orbimed advisors reduces stake in Passage Bio for $142,223 By Investing.com - Investing.com South Africa
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MSN
Orbimed advisors reduces stake in Passage Bio for $142,223 - Investing.com
Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel to Monitor Treatment Journey for Patients with Traumatic Brain Injury and Alzheimer's - BioSpace
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway - BioSpace
Geode Capital Management LLC Has $351,000 Position in Nutriband Inc. (NASDAQ:NTRB) - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Geode Capital Management LLC - Defense World
Head-To-Head Comparison: Passage Bio (NASDAQ:PASG) vs. JATT Acquisition (NYSE:JATT) - Defense World
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Passage Bio announces data from upliFT-D study in FTD-GRN, provides update - TipRanks
Passage Bio Restructures and Extends Cash Runway - TipRanks
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates - The Manila Times
Passage Bio's FTD Treatment Shows Promise in Clinical Trial, Plans Lower Dose Strategy - StockTitan
Orbimed advisors sells shares in Passage Bio for $103,305 By Investing.com - Investing.com Canada
Orbimed advisors sells shares in Passage Bio for $103,305 - Investing.com India
Frontotemporal Dementia Clinical and Non-Clinical Studies, - openPR
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 7, 2025 - BioSpace
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage Bio sees $241,038 stock purchase by Lynx1 Capital - Investing.com Australia
Passage Bio (NASDAQ:PASG) & Apogee Therapeutics (NASDAQ:APGE) Head-To-Head Contrast - Defense World
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely? - Yahoo Finance
Orbimed advisors sells $138,192 in Passage Bio shares By Investing.com - Investing.com Nigeria
Orbimed advisors sells $138,192 in Passage Bio shares - Investing.com India
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - BioSpace
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):